The prognostic value of PD‐L1 expression in upper tract urothelial carcinoma varies according to platelet count

Autor:	Yu Miyama, Teppei Morikawa, Jimpei Miyakawa, Yuichi Koyama, Taketo Kawai, Haruki Kume, Masashi Fukayama
Jazyk:	angličtina
Rok vydání:	2018
Předmět:	host–tumor interaction immune checkpoint inhibitor serum marker upper urinary tract carcinoma urothelial cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Zdroj:	Cancer Medicine, Vol 7, Iss 9, Pp 4330-4338 (2018)
Druh dokumentu:	article
ISSN:	2045-7634
DOI:	10.1002/cam4.1686
Popis:	Abstract Programmed cell death ligand‐1 (PD‐L1) is a ligand for programmed cell death‐1 (PD‐1) that negatively regulates T‐cell activation and plays a crucial role in suppressing anti‐tumor host immunity. Although PD‐L1 is a promising immunotherapy target in various cancers, including urothelial carcinoma (UC), the prognostic significance of PD‐L1 in UC is unclear. As platelets help protect tumor cells from immune elimination in the circulatory system, we hypothesized that tumor PD‐L1 and circulating platelets might synergistically promote tumor metastasis, and that the prognostic significance of PD‐L1 might vary according to platelet count. We immunohistochemically examined tumor PD‐L1 expression in 271 patients with upper tract UC, which revealed PD‐L1 positivity in 31 of 271 cases (11%). The associations of tumor PD‐L1 expression with outcomes varied among patients with high or low platelet counts (Pinteraction
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/ed5a8ca77930448ea95bdce11fcf3af8 Zobrazit plný text záznamu View record in DOAJ Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.